dostęp płatny
Tom 4, Nr 1 (2023)
OPINIA EKSPERTÓW
Wysłany: 2023-07-06
Opublikowany online: 2023-07-06
Pobierz cytowanie
Stanowisko ekspertów dotyczące leczenia uzupełniającego ozymertynibem chorych na niedrobnokomórkowego raka płuca po radykalnej resekcji nowotworu
1, 2, 2, 3, 4, 5, 67
Pneum Pol 2023;4(1):33-46.
Afiliacje- Zakład Patomorfologii, Instytut Gruźlicy i Chorób Płuc, Warszawa
- Klinika Nowotworów Płuca i Klatki P iersiowej, Narodowy Instytut Onk ologii im. Marii Skłodowskiej- Curie — Państwowy Instytut Badawczy, Warszawa
- Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Warszawski Uniwersytet Medyczny
- Klinika Chirurgii, Instytut Gruźlicy i Chorób Płuc, Warszawa
- Klinika Chirurgii Klatki P iersiowej, Gdański Uniwersytet Medyczny
- Katedra i Zakład Biologii i Genetyki Medycznej, Gdański Uniwers ytet Medyczny, Gdańsk
- Laboratorium Genetyki Klinicznej, Uniwersyteckie Centrum Klinic zne, Gdańsk
dostęp płatny
Tom 4, Nr 1 (2023)
OPINIE EKSPERTÓW
Wysłany: 2023-07-06
Opublikowany online: 2023-07-06
Streszczenie
Brak
Streszczenie
Brak
Pełny tekst:
Dodaj do koszyka: 49,00 PLN
Pobierz cytowanie
Informacje o artykuleTytuł
Stanowisko ekspertów dotyczące leczenia uzupełniającego ozymertynibem chorych na niedrobnokomórkowego raka płuca po radykalnej resekcji nowotworu
Czasopismo
Numer
Typ artykułu
OPINIA EKSPERTÓW
Strony
33-46
Opublikowany online
2023-07-06
Wyświetlenia strony
183
Wyświetlenia/pobrania artykułu
8
Rekord bibliograficzny
Pneum Pol 2023;4(1):33-46.
Autorzy
Renata Langfort
Maciej Krzakowski
Dariusz M. Kowalski
Rafał Krenke
Tadeusz Orłowski
Witold Rzyman
Bartosz Wasąg
Referencje (42)- Wojciechowska U, Barańska K, Michałek I, et al. Nowotwory złośliwe w Polsce w 2020 roku. Krajowy Rejestr Nowotworów. Warszawa 2022. . https://onkologia.org.pl/sites/default/files/publications/2023-01/nowotwory_2020.pdf.
- Goldstraw P, Chansky K, Crowley J, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1): 39–51.
- Karacz CM, Yan J, Zhu H, et al. Timing, Sites, and Correlates of Lung Cancer Recurrence. Clin Lung Cancer. 2020; 21(2): 127–135.e3.
- Pignon JP, Tribodet H, Scagliotti GV, et al. LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21): 3552–3559.
- Krzakowski M, Jassem J, Antczak A, et al. Thoracic neoplasms. Oncology in Clinical Practice. 2022; 18(1): 1–39.
- Sullivan I, Planchard D. Next-Generation Tyrosine Kinase Inhibitors for Treating -Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2016; 3: 76.
- Wu YL, Tsuboi M, He J, et al. ADAURA Investigators. Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(18): 1711–1723.
- Wu YL, John T, Grohe C, et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2022; 17(3): 423–433.
- Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006; 30(5): 787–792.
- Darling GE, Allen MS, Decker PA, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial. Chest. 2011; 139(5): 1124–1129.
- Patomorfologia: standardy i przykłady dobrej praktyki oraz elementy diagnostyki różnicowej. Wytyczne dla zakładów/pracowni patomorfologii 2020.
- Standardy organizacyjne oraz standardy postępowania w patomorfologii. Wytyczne dla zakładów/pracowni patomorfologii 2020.
- Program Akredytacji Jednostki Diagnostyki Patomorfologicznej. Zestaw standardów. CMJ, Kraków 2021.
- Darling GE. Current status of mediastinal lymph node dissection versus sampling in non-small cell lung cancer. Thorac Surg Clin. 2013; 23(3): 349–356.
- Langfort R, Chyczewski L, Szołkowska M, et al. Płuco. Standardy oceny mikroskopowej materiału biopsyjnego i operacyjnego u chorych na nowotwory złośliwe. Pol J Pathol. 2015; 66(suppl. 1): 22–24.
- Boyle DP, Allen DC. Histopathology reporting. Guidelines for surgical cancer. 4th ed Springer. ; 2020.
- Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Handbook. 7th ed. AJCC, Springer 2010.
- Pfeifer JD, Humphrey PA, Ritter JH, Dehner LP. The Washington Manual of Surgical Pathology. 3rd ed. Wolters Kluwer, Philadelphia 2020.Pfeifer JD, Humphrey PA, Ritter JH, Dehner LP. The Washington Manual of Surgical Pathology. 3rd ed. Wolters Kluwer, Philadelphia 2020.
- WHO Clasification of Tumours Editorial Board. Thoracic tumours. In: WHO classification of tumours series, 5th ed.; vol. 5. International Agency for Research on Cancer, Lyon 2021.
- Moreira AL, Ocampo PSS, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020; 15(10): 1599–1610.
- Travis WD, Brambilla E, Rami-Porta R, et al. International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008; 3(12): 1384–1390.
- Rami-Porta R. Staging Manual in Thoracic Oncology. 2nd ed. IASLC, North Fort Myers, FL 2016.
- Travis WD, Asamura H, Bankier AA, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and Advisory Board Members. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016; 11(8): 1204–1223.
- Rami-Porta R. The Evolving Concept of Complete Resection in Lung Cancer Surgery. Cancers (Basel). 2021; 13(11).
- Langfort R. Nowotwory klatki piersiowej. Rak płuca. In: Nasierowska-Guttmejer A, Górnicka B. ed. Zalecenia do diagnostyki histopatologicznej nowotworów. Centrum Onkologii, PTP 2013: 47–62.
- Pisters K, Kris MG, Gaspar LE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA NSCLC Guideline Expert Panel. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022; 40(10): 1127–1129.
- Solomon B, Ahn J, Barlesi F, et al. ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2019; 37(15_suppl): TPS8569–TPS8569.
- Goldman J, Besse B, Wu Y, et al. P01.01 LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC. Journal of Thoracic Oncology. 2021; 16(10): S975–S976.
- https://www.clinicaltrials.gov/ct2/show/NCT04302025.
- https://www.clinicaltrials.gov/ct2/show/NCT04926831.
- Yuan M, Huang LL, Chen JH, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019; 4: 61.
- Isla D, Lozano MD, Paz-Ares L, et al. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2023; 25(5): 1252–1267.
- Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(11): 1491–1505.
- Schrock AB, Frampton GM, Herndon D, et al. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. Clin Cancer Res. 2016; 22(13): 3281–3285.
- Suh JH, Schrock AB, Johnson A, et al. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist. 2018; 23(7): 776–781.
- https://www.clinicaltrials.gov/ct2/show/NCT04302025 (13.04.2023).
- https://www.clinicaltrials.gov/ct2/show/NCT04926831 (13.04.2023).
- Wolff HB, Steeghs EMP, Mfumbilwa ZA, et al. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands. JCO Precis Oncol. 2022; 6: e2200201.
- Steeghs EMP, Groen HJM, Schuuring Ed, et al. PATH consortium. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer. 2022; 167: 87–97.
- Dall'Olio FG, Conci N, Rossi G, et al. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience. Lung Cancer. 2020; 149: 5–9.
- Kuang S, Fung AS, Perdrizet KA, et al. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. Curr Oncol. 2022; 29(7): 4428–4437.
- Wu YL, Tsuboi M, Grohe C, et al. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. Annals of Oncology. 2022; 33: S1548–S1549.
